DRP: Developmental Research Program

DRP：发展研究计划

• 批准号: 10713058
• 负责人: Alexander Olawaiye
• 金额: $ 11.09万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10713058
• 关键词: Advocate; Annual Reports; Application procedure; Area; Award; Bioinformatics; Biometry; Cancer Center; Cancer Research Project; Cessation of life; Clinical; Clinical Trials; Collaborations; Communities; Core Facility; Data; Development; Disease; Doctor of Philosophy; Early Diagnosis; Electronic Mail; Eligibility Determination; Ensure; Extramural Activities; Feedback; Financial Support; Fostering; Funding; Goals; Hospitals; Incubators; Individual; Infrastructure; Institution; Investments; Joints; Laboratories; Lead; Malignant Neoplasms; Malignant neoplasm of ovary; Mentors; Minority; Minority-Serving Institution; Monitor; Morbidity - disease rate; Outcome; Patients; Peer Review; Pilot Projects; Population; Population Sciences; Prevention; Process; Prognostic Marker; Program Research Project Grants; Progress Reports; Research; Research Personnel; Research Project Grants; Resources; Science; Scientist; Sister; Specimen; Testing; Tissues; Underrepresented Minority; United States National Institutes of Health; Universities; Vertebral column; Woman; Work; anticancer research; cohort; disability; equity, diversity, and inclusion; experience; flexibility; high reward; high risk; innovation; inter-institutional; meetings; member; minority investigator; mortality; mouse model; next generation; novel; outreach; peer; predictive marker; programs; recruit; repository; standard of care; success; therapy resistant; translational impact; tumorigenesis; web site

PROJECT SUMMARY – DEVELOPMENTAL RESEARCH PROGRAM (DRP) The Developmental Research Program (DRP) of the UPMC Hillman Cancer Center (HCC) Ovarian Cancer SPORE seeks to fund and facilitate translationally-driven, innovative pilot projects in ovarian cancer. The overarching goal is to decrease ovarian cancer morbidity and mortality through stimulating new research in the areas of prevention and early detection; mechanisms of tumorigenesis and therapeutic resistance; predictive and prognostic biomarkers; and novel targets and approaches to therapy. An additional goal of the DRP is to establish support for underrepresented minorities in ovarian cancer research. To accomplish these goals, DRP will build on the successful program and infrastructure developed via a previous joint P50 award that resulted in an approximate 35-fold return on investment. The DRP will widely solicit proposals annually using local and national networks. To increase recruitment of underrepresented minorities to our DRP program, DRP will leverage University of Pittsburgh and HCC programs with Minority Serving Institutions to increase the participation of under-represented scientists. Additionally, members of the Internal and External Advisory Boards will be encouraged to identify investigators who could contribute to the diversity of the DRP. The most meritorious proposals will be selected based on an NIH-style two-tiered review to ensure rigor and absence of bias. The DRP Co-Directors, SPORE Executive Committee, Patient Advocates, and SPORE investigators will participate in the first-tier scientific review, together with ad hoc revewers when necessary. The final selection of awardees will be made following a second-tier programmatic review involving the SPORE Internal Advisory Board. Each award will provide $50,000 in funds, with half of the monies coming from the DRP and the other half from HCC, demonstrating substantial institutional commitment. DRP will fund three pilots per year, reserving one for an underrepresented minority investigator. DRP awardees new to ovarian cancer will be assigned an experienced mentor to provide guidance and integration into the SPORE. Awardees will be provided full access to the HCC Ovarian Cancer SPORE Core resources, including tissue specimens and bioinformatic/biostatistical support, not only to ensure project success but also to support subsequent funding applications outside the SPORE mechanism. All DRP awardees will meet bi-annually with the DRP Co- Directors, prepare progress reports annually, and make research presentations at SPORE meetings. Those that demonstrate significant research progress will be eligible for competitive renewal for a second year. Exceptional pilots with potential for significant translational impact can be elevated to full SPORE projects. The DRP provides a vital mechanism for achieving the SPORE’s goal of developing a diverse pool of ovarian cancer researchers committed to overcoming this deadly disease.

项目摘要 – 发展研究计划 (DRP) UPMC 希尔曼癌症中心 (HCC) 卵巢癌发展研究计划 (DRP) SPORE 寻求资助和促进卵巢癌转化驱动的创新试点项目。 总体目标是通过刺激新的研究来降低卵巢癌的发病率和死亡率 预防和早期检测领域；肿瘤发生和治疗耐药的机制； DRP 的另一个目标是： 为了实现这些目标，DRP 为卵巢癌研究中代表性不足的少数群体提供支持。 将建立在之前 P50 联合奖项所开发的成功计划和基础设施的基础上 DRP 每年将利用当地和当地政府广泛征求建议书，以实现约 35 倍的投资回报。 为了增加代表性不足的少数族裔参与我们的 DRP 计划，DRP 将 利用匹兹堡大学和 HCC 项目以及少数族裔服务机构来增加 代表性不足的科学家以及内部和外部咨询成员的参与。 将鼓励董事会确定能够为 DRP 多样性做出贡献的调查员。 优秀的提案将根据 NIH 式的两级审查来选择，以确保严格和不存在 DRP 联合主任、SPORE 执行委员会、患者权益倡导者和 SPORE 调查人员将避免偏见。 参与一级科学评审，必要时会同特设评审员进行最终评选。 获奖者名单将在涉及 SPORE 内部咨询的二级计划审查后确定 每个奖项将提供 50,000 美元的资金，其中一半来自 DRP，另一半来自 DRP。 一半来自 HCC，表明 DRP 每年将资助三个试点， 为代表性不足的少数族裔研究人员保留一个新的卵巢癌研究人员。 指定一位经验丰富的导师为获奖者提供指导并帮助其融入 SPORE。 提供对 HCC 卵巢癌 SPORE 核心资源的完全访问，包括组织标本和 生物信息/生物统计支持，不仅确保项目成功，而且支持后续资金 SPORE 机制之外的所有 DRP 获奖者将每两年与 DRP Co- 会面一次。 董事每年准备进度报告，并在 SPORE 会议上进行研究报告。 那些表现出重大研究进展的项目将有资格获得第二年的竞争性更新。 具有重大转化影响潜力的杰出试点可以提升为完整的 SPORE 项目。 DRP 为实现 SPORE 开发多样化卵巢池的目标提供了重要机制 癌症研究人员致力于克服这种致命疾病。